COVID-19

Here’s a roundup of the latest coronavirus-related news.

Pfizer and BioNTech have initiated rolling submission of their Biologics License Application for full approval of BNT162b2.

Here’s a roundup of the latest coronavirus-related news.

“This Is Our Shot” campaign aims to promote COVID-19 vaccination, address vaccine hesitancy, and acknowledge the disproportionately higher infection rates among Black communities.

The future of clinical trials in a post pandemic world will rely on a patient-centered approach. Pharmacists can play a role to caring for these patients.

A committee of vaccine advisers to the CDC convened to discuss the risk of a rare blood clotting condition linked to the Johnson & Johnson COVID-19 vaccine.

Here’s a roundup of the latest coronavirus-related news.

The European Medicines Agency determined that the benefits of Johnson & Johnson’s COVID-19 vaccine outweigh the risks. The vaccine is still paused in the United States.

Beginning this week, the OTC self-administered rapid antigen test will be available in Walgreens stores for $23.99.

Here's a roundup of the latest coronavirus-related news.

A new survey conducted by NCPA showed that many independents are serving vulnerable populations but are not receiving adequate supplies of COVID-19 vaccine.

Authors of a paper published in Neurology suggest that a case of Guillain-Barré Syndrome reported in a COVID-19 vaccine trial may have been a coincidence.

The CDC and FDA will further investigate the reports of blood clots following administration of the vaccine.

A recent study examined persistent symptoms following mild COVID-19 infection.

Here's the roundup of COVID-19 related news from this week.

A session at the American Pharmacists Association 2021 Annual Meeting and Exposition addressed recent immunization practice changes.

In part 2 of our interview, Rich Tremonte of AmerisourceBergen discusses distribution highlights, inspiring efforts from pharmacists, and the future of COVID-19 vaccination.

The FDA has made revisions to the emergency use authorization for the Moderna COVID-19 vaccine.

Here’s an overview of what’s in the late-stage pipeline.

Rich Tremonte from AmerisourceBergen discusses community pharmacy's integral role in the rollout of COVID-19 vaccines and highlights some inspiring stories from community pharmacists.

Here’s a roundup of the latest coronavirus-related news.

The vaccine is 91.3% effective against COVID-19 for up to 6 months after the second dose, according to an analysis of data collected through March 13.

Pfizer/BioNTech released data on their COVID-19 vaccine that indicates high efficacy in children aged 12 to 15 years.

A retrospectively analysis assessed the effect of a remote vaccination review process on vaccination status during the COVID-19 pandemic.

A team of researchers have released study results that show the Moderna and Pfizer vaccines are indeed safe and effective for this population.